4294-95-5

Basic information

• Product Name: 2-AMINO-4-METHOXY-BENZOIC ACID
• Synonyms: 2-AMINO-4-METHOXY-BENZOIC ACID;4-METHOXY-2-AMINO-BENZOIC ACID;4-METHOXYANTHRANILIC ACID;2-AMINO-4-METHOXYBENZOIC ACID ---OFF-WHITE POWDER, 99%---;2-amine-4-methoxybenzoic acid;2-azanyl-4-methoxy-benzoic acid;4-Methoxyanthranilic acid, 2-Carboxy-5-methoxyaniline, 3-Amino-4-carboxyanisole;4-METHOXY-2-AMINO-BENZOIC ACID(or 4-METHOXYANTHRANILIC ACID)
• CAS NO: 4294-95-5
• Molecular Formula: C₈H₉NO₃
• Molecular Weight: 167.16
• Product Categories: pharmacetical
• Mol File: 4294-95-5.mol
• Article Data: 22

Chemical Properties

• Melting Point: 174-177°C
• Boiling Point: 339.8 °C at 760 mmHg
• Flash Point: 159.3 °C
• Appearance: /
• Density: 1.303 g/cm³
• Vapor Pressure: 3.47E-05mmHg at 25°C
• Refractive Index: 1.603
• Storage Temp.: Keep in dark place,Sealed in dry,Room Temperature
• PKA: 5.21±0.10(Predicted)
• CAS DataBase Reference: 2-AMINO-4-METHOXY-BENZOIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: 2-AMINO-4-METHOXY-BENZOIC ACID(4294-95-5)
• EPA Substance Registry System: 2-AMINO-4-METHOXY-BENZOIC ACID(4294-95-5)

Safety Data

• Hazard Codes: Xn
• Statements: 36/37/38-22
• Safety Statements: 26-36/37/39-37
• WGK Germany: 3
• HazardClass: IRRITANT
• Hazardous Substances Data: 4294-95-5(Hazardous Substances Data)

Usage

Chemical Properties

Yellow powder

Uses

2-Amino-4-methoxybenzoic Acid, is an organic building block used in the synthesis of various chemical compounds.

InChI:InChI=1/C8H9NO3/c1-12-5-2-3-6(8(10)11)7(9)4-5/h2-4H,9H2,1H3,(H,10,11)

Upstream product

• 2836-00-2 3-amino-4-methylphenol 
• 38469-83-9 4-methoxy-2-nitro-benzonitrile 
• 50413-30-4 methyl 2-amino-4-methoxybenzoate 
• 153898-63-6 2-iodo-5-methoxyaniline 
• 33844-21-2 2-nitro-4-methoxybenzoic acid 
• 118-92-3 anthranilic acid 
• 38487-91-1 2-amino-p-anisamide 
• 7440-05-3 palladium 
• 621-42-1 meta-hydroxyacetanilide 
• 50868-75-2 5’-methoxy-2’-methylacetanilide 
• 17484-36-5 4-Methyl-3-nitroanisole 
• 96-96-8 4-methoxy-2-nitroaniline 
• 536-90-3 m-Anisidine 
• 6966-87-6 2-(hydroxyimino)-N-(3-methoxyphenyl)acetamide 

Downstream Products

• 2142-05-4 2-(3-methoxyphenyl)-1H-isoindole-1,3(2H)-dione 
• 16064-24-7 7-methoxyquinazoline-4(3H)-one 
• 19218-83-8 5-methoxydiphenylamine-2-carboxylic acid 
• 872279-05-5 2-(9,10-dioxo-9,10-dihydro-[1]anthrylamino)-4-methoxy-benzoic acid 
• 103203-39-0 2-[(carboxymethyl)thio]-4-methoxybenzoic acid 
• 21971-21-1 2-chloro-4-methoxybenzoic acid 
• 38918-51-3 7-methoxy-2-[4-methoxy-2-(toluene-4-sulfonylamino)-phenyl]-benzo[d][1,3]oxazin-4-one 
• 112239-02-8 4-Methoxy-2-(2-methoxycarbonyl-phenylamino)-benzoic acid 
• 117979-56-3 2-(2-acetyloxyphenyl)-7-methoxy-4H-3,1-benzoxazin-4-one 
• 766-85-8 3-methoxy-1-iodobenzene 
• 54435-09-5 2-iodo-4-methoxybenzoic acid 
• 848142-85-8 2-azido-4-methoxybenzoic acid 
• 55496-52-1 4-chloro-7-methoxy-quinazoline 
• 62484-31-5 2,4,-dichloro-7-methoxyquinazoline 

Relevant articles and documents

Discovery of Novel Tacrine-Pyrimidone Hybrids as Potent Dual AChE/GSK-3 Inhibitors for the Treatment of Alzheimer's Disease

Based on a multitarget strategy, a series of novel tacrine-pyrimidone hybrids were identified for the potential treatment of Alzheimer's disease (AD). Biological evaluation results demonstrated that these hybrids exhibited significant inhibitory activities toward acetylcholinesterase (AChE) and glycogen synthase kinase 3 (GSK-3). The optimal compound 27g possessed excellent dual AChE/GSK-3 inhibition both in terms of potency and equilibrium (AChE: IC50 = 51.1 nM; GSK-3β: IC50 = 89.3 nM) and displayed significant amelioration on cognitive deficits in scopolamine-induced amnesia mice and efficient reduction against phosphorylation of tau protein on Ser-199 and Ser-396 sites in glyceraldehyde (GA)-stimulated differentiated SH-SY5Y cells. Furthermore, compound 27g exhibited eligible pharmacokinetic properties, good kinase selectivity, and moderate neuroprotection against GA-induced reduction in cell viability and neurite damage in SH-SY5Y-derived neurons. The multifunctional profiles of compound 27g suggest that it deserves further investigation as a promising lead for the prospective treatment of AD.

Antituberculosis Activity of the Antimalaria Cytochrome bcc Oxidase Inhibitor SCR0911

The ability to respire and generate adenosine triphosphate (ATP) is essential for the physiology, persistence, and pathogenicity of Mycobacterium tuberculosis, which causes tuberculosis. By employing a lead repurposing strategy, the malarial cytochrome bc

NOVEL ANTI-INFLAMMATORY AGENTS

Disclosed are methods of regulating interleukin-6 (IL-6) and/or vascular cell adhesion molecule-1 (VCAM-1) and methods of treating and/or preventing cardiovascular and inflammatory diseases and related disease states, such as, for example, atherosclerosis, asthma, arthritis, cancer, multiple sclerosis, psoriasis, and inflammatory bowel diseases, and autoimmune disease(s) by administering a naturally occurring or synthetic quinazolone derivative. The invention provides novel synthetic quinazolone compounds, as well as pharmaceutical compositions comprising those compounds.